Market Performance of Arcutis Biotherapeutics (ARQT)
On Thursday, 22 September 2026, the Nasdaq‑listed biopharmaceutical company Arcutis Biotherapeutics (ticker ARQT) closed its trading session up by 2.92 %, reaching a price of USD 31.87. This uptick contributed to a 24‑hour trading volume of USD 147.4 million, a figure that represents a notable portion of the 125.7 million shares outstanding.
Over the preceding month, the stock has experienced a substantial rally, posting an increase of 26.43 %. The current market capitalization stands at USD 4 billion, placing ARQT among the larger mid‑cap biopharma firms listed on the Nasdaq exchange.
The 200‑day simple moving average (SMA) sits at USD 25.11, indicating that the recent price rise is above the long‑term trendline and may signal a bullish momentum. The company’s price has achieved a new 52‑week high of USD 33.30 on 20 October 2026, while its lowest point over the same period was USD 19.30 on 19 May 2026. These extremes illustrate the volatility typical of the biopharmaceutical sector, where clinical milestones can cause rapid shifts in investor sentiment.
Comparative Performance of Peer Stocks
In the same 24‑hour period, the following peer companies exhibited the following performance:
| Company | Ticker | 24‑hour Change | Current Price (USD) | Market Capitalisation (USD) | P/E Ratio |
|---|---|---|---|---|---|
| Kodiak Gas Services | KGS | +0.57 % | 49.02 | 4.8 billion | 70.84 |
| Billiontoone Cl | BLLN | +2.44 % | 104.67 | 4.8 billion | 137.73 |
| Legence | LGN | –6.74 % | 41.55 | 4.8 billion | – |
| Spire | SR | +2.12 % | 82.51 | 4.8 billion | 17.91 |
| Travere Therapeutics | TVTX | +3.58 % | 52.58 | 4.8 billion | – |
While ARQT’s performance is modest compared to some peers, its upward trajectory aligns with the broader trend among biopharmaceutical stocks that have recently seen positive developments in clinical research and regulatory submissions.
Company Overview
Arcutis Biotherapeutics, Inc., headquartered in Westlake Village, United States, focuses on the development of therapies for immune‑mediated diseases and conditions that currently lack effective treatments. The company’s pipeline includes candidates that target complex inflammatory pathways, positioning it to address significant unmet medical needs. Investors can review the company’s research priorities, clinical milestones, and corporate strategy on its official website at www.arcutis.com .
The information presented herein is sourced from market data and public disclosures. It is intended for informational purposes only and does not constitute investment advice.
